SecBot SecBot
SECBOTREPLAY Home › Report › MTRI

MTRI · CEO Form 3 filed

InMed Pharmaceuticals Inc. · 3 filed Nov 12, 2026 at 16:01 ET

At the news

NEUTRALIMPACT 2/10

3 filed Nov 12, 2026 at 16:01 ET

Gregory Divis filed a Form 3 initial statement of beneficial ownership after becoming President and CEO of InMed Pharmaceuticals Inc. (now Mentari Therapeutics Inc.) following a merger. The filing discloses options to purchase 1,454,398 shares at $10.37, vesting over three years. This is a routine Section 16 filing with no material price impact.

  • Gregory Divis appointed President and CEO of InMed Pharmaceuticals Inc. (now Mentari Therapeutics Inc.)
  • Filing is an initial statement of beneficial ownership (Form 3) under Section 16(a)
  • Divis holds stock options to buy 1,454,398 shares at $10.36 per share
  • Options vest 25% on July 20, 2027 and monthly thereafter through July 20, 2030

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access